← Russell 3000 cross-section

MASS 908 Devices Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$448m
Revenue TTM
$61m
Net income TTM
$-35m
Free cash flow
$1m
Composite score
48.8
Sector rank
#2446

Valuation

P / E
EV / EBITDA
EV / sales
5.7
FCF yield
0.14%
Earnings yield vs 10-yr
-12.47pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-57.0%
EBITDA margin
-56.2%
ROE
-27.3%
ROIC
-154.3%
Revenue growth
0.7%

Insider activity, last 90 days

Net open-market
$-4.65m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Device sales Our financial performance has largely been driven by, and in the future will continue to be impacted by, the rate of sales of our handheld devices. We expect our device sales to continue to grow as we increase penetration in our existing markets and expand into, or offer new features and solutions that appeal to, new markets. Recurring revenue was 30% and 36% of total revenue for the six months ended June 30, 2026 and 2025, respectively. As our device installed base expands, recurring revenue on an absolute basis is expected to increase and over time should be an increasingly important contributor to our revenue. …908 Devices Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →